Liposome Formulation for Parasitic Diseases and Infections Research
Inquiry
Liposomes have shown significant potential in combating various parasitic diseases, including malaria, leishmaniasis, and Chagas disease. They are also effective carriers for antifungal medications, treating systemic fungal infections like those caused by Candida albicans and Aspergillus fumigatus, with greater effectiveness and lower toxicity compared to traditional drugs. CD Formulation focuses on advancing the use of liposomes for anti-parasitic and anti-infective research through our robust platform and technologies.
Advantages of Liposome Systems in Infectious Disease Research
Liposomes play a crucial role in the development of drug formulations for parasitic, bacterial, and fungal infections. The liver, often a target for parasites, can be effectively targeted using liposomal delivery systems. Liposomes offer enhanced drug delivery with the following benefits:
- Targeted therapy: Liposomes can deliver drugs to specific organs or sites, thereby improving therapeutic effects and reducing toxicity. For example, liposomes can bind to antibodies, proteins, or enzymes and deliver bioactive compounds directly to the infected site.
- Improved stability: Liposomes can encapsulate drugs to prevent them from degrading in the body, thereby improving the bioavailability of drugs and addressing issues such as poor solubility and low permeability in water.
- Controlled release: Liposomes can release drugs in a controlled manner, helping to slow the progression of resistance.
- Synergistic effects: Liposomes can enhance the efficacy of anti-parasitic drugs without causing toxicity to host cells. For example, liposomes can deliver antigens as vaccine candidates to elicit a strong immune response to clear infections.
- Multiple administration routes: The administration routes are diverse, including oral, transdermal, and intranasal administration methods.
Fig.1 Schematic representation of the main advantages of liposomes as antibiotic carriers. (Ferreira M, et al, 2021)
Main Applications of Liposomes in Parasitic Diseases and Infections Research
Liposomal-encapsulated antibiotics demonstrate efficacy against infections caused by facultative intracellular bacteria, parasites (such as Leishmania), and viruses (such as the virus responsible for Rift Valley fever). CD Formulation provides specialized liposome solutions for research on parasitic diseases and infections.
Therapy and Targeted Delivery |
Case Studies |
- Treatment for Malaria. Malaria parasite resistance and toxicity of antimalarial drugs pose a challenge to treatment. We utilize liposomal controlled release techniques and try to offer solutions to address these limitations.
|
Fig.2 Reparation and assessment of liposomes targeting the brain for anti-malarial therapy. (Tian, Ya, et al, 2022) |
- Leishmaniasis.One of the primary challenges in treating leishmaniasis is the difficulty in targeting drugs to the infected area. Leveraging liposome targeting technology enables us to offer a wider range of potential solutions to this issue.
|
Fig.3 Preparation and assessment of liposomes targeting the brain for anti-malarial therapy. (Tambe S, et al, 2024) |
- Chagas Disease. Chagas disease drugs have limited effectiveness due to poor cell entry, but liposomes may improve insoluble drug delivery. We are trying to alleviate this limitation with the advantages of liposomes in insoluble drugs.
|
Fig.4 In vivo mechanism for Chagas disease. (Machado, Fabiana., et al, 2012) |
- Human African Trypanosomiasis. Currently, the treatment options for HAT have limitations and side effects, so there is an urgent need to explore new therapies.
|
Fig.5 Nanocarriers proposed for the delivery of PTM in different therapeutic approaches. (Machado, Fabiana., et al, 2022) |
Vaccines |
Specific Cases |
Liposomes are used to create new vaccines that boost immune responses, targeting specific T cell subsets and enhancing mucosal or systemic immunity by combining recombinant antigens with modulating adjuvants. |
Fig.6 Various modes of liposome-antigen association. (Giddam, Ashwin Kumar, et al, 2012) |
Diagnostics |
Case Studies |
Currently, nanoparticles or liposome carriers have demonstrated efficacy in parasite diagnosis.
- Diagnosis of malaria. For example, gold nanoparticles functionalized with antibodies targeting malaria biomarkers (such as HRP2) are utilized for early detection and diagnosis of malaria.
- Diagnosis of leishmaniasis. Liposomal amphotericin B, another successful case, can be employed for confirming the diagnosis of leishmaniasis following serological or skin tests.
|
Fig.7 Chunap (Chagas urine nanoparticle assay) assay for the early diagnosis of congenital Chagas disease. (Quijia, Christianr, et al, 2019) |
Our Capabilities on Liposomal Drugs for Parasitic Diseases and Infections Research
Fig.8 Our capabilities on parasitic diseases and infections research. (CD Formulation)
CD Formulation offers a range of services to support your research:
- Targeting technology: Expertise in both active and passive targeting, including long-cycle liposomes, glycosylated modifications, immune liposomes, and responsive technologies.
- Formulation Development: Comprehensive support from initial R&D to formulation optimization.
- Multiple Drug Delivery Routes: Proficient in developing liposome formulations for inhalation, oral, and transdermal delivery.
- Controlled Release Technology: Combining exogenous stimuli with liposome release mechanisms for efficient drug delivery.
- Liposome Characterization: In-depth evaluation of in vitro release, cytotoxicity, cell uptake, size, encapsulation efficiency, and stability.
- Solvent Removal Techniques: Utilizing gel filtration, vacuum evaporation, centrifugation, dialysis, and nitrogen blow technology to eliminate organic solvents effectively.
Explore Our Liposome Services for Anti-Parasitic and Anti-Infective Research
Injectable Liposome Formulation Development
Our services cover the entire R&D process of injectable liposome development, including formulation design and screening, in vitro pharmacodynamic evaluation, testing phase and mass production challenges.
Custom Long-circulating Liposome Service
We can provide modification services for derivatives, and colleagues can provide PEG-modified liposomes with different chain lengths. we help our customers explore more alternative long-circulating liposomes to PEG modifications that avoid the ABC effects caused by such PEG liposomes.
Universal Liposome Characterization
We offer comprehensive characterization services for these parameters, such as liposome morphology, surface characteristics, structure and integrity, charge distribution, drug encapsulation efficiency, phase transition temperature, particle size distribution, etc.
Custom Polymer-modified Liposome Service
We provide screening services and provide the polymer or copolymer, polymer derivatives, including, chitosan, atelocollagen, modified xanthan gum department, alginate, cyclodextrin, gelatin, poly (acrylic acid), etc.
Custom Reactive Oxygen Species (ROS)-responsive Liposome Service
Our ROS-responsive liposome development platform enables the formulation of functional liposomes for different disease research, including research for atherosclerotic lesion areas, tumor drugs, diabetes complications, Cardiac repair disorders after myocardial ischemia-reperfusion (MI/R) injury, etc.
As a leader in liposome technology, CD Formulation is dedicated to providing researchers with advanced liposomal solutions to further the development of effective treatments against parasitic and infectious diseases. Contact us to learn how we can assist with your research needs.
References
- Ferreira M, Ogren M, et al. Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance. Molecules. 2021 Apr 2; 26(7): 2047.
-
Tian, Ya & Zhongyuan, Zheng; et al. Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria. Journal of Nanobiotechnology. 2022. 20. 10.1186.
- Giddam, Ashwin Kumar; Zaman, Mehfuz; et al. Liposome-Based Delivery System for Vaccine Candidates: Constructing An Effective Formulation. Nanomedicine (London, England). 2012. 7. 1877-93. 10.2217.
- Tambe S, Nag S, et al. Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review. ACS Infectious Diseases. 2024 Jun 3.
- Machado, Fabiana., Dutra, Walderez., et al. Current Understanding of Immunity to Trypanosoma cruzi Infection and Pathogenesis of Chagas Disease. Seminars in immunopathology. 2012. 34. 10.1007.
- Andreana, I., Bincoletto, V., et al. Nanotechnological approaches for pentamidine delivery. Drug Deliv. and Transl. Res. 2022, 12, 1911-1927.
- Quijia, Christian; Azevedo, Clênia; et al. Advances in nanocarriers as drug delivery systems in Chagas disease. International Journal of Nanomedicine. 2019. 14. 6407-6424. 10.2147.
How It Works
STEP 2
We'll email you to provide your quote and confirm order details if applicable.
STEP 3
Execute the project with real-time communication, and deliver the final report promptly.
Related Services